Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC - Gao, Shugeng; Li, Ning; Gao, Shunyu; Xue, Qi; Ying, Jianming; Wang, Shuhang; Tao, Xiuli; Zhao, Jun; Mao, Yousheng; Wang, Bing; Shao, Kang; Lei, Wendong; et al. (Journal of thoracic oncology, 2020)
Keywords: Antibodies, Monoclonal, Humanized - therapeutic use; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms - drug therapy; Neoadjuvant; Neoadjuvant Therapy; NSCLC; PD-1 inhibitor; PD-L1 expression; SUVmax; PD-L1 expression; SUVmax; Neoadjuvant; PD-1 inhibitor; NSCLC